Arginine vasopressin (AVP) is a potent vasopressor and antidiuretic neurohormone. However, when administered intravenously to humans, AVP causes forearm vasodilation. This effect has been attributed to sympathetic withdrawal, secondary to AVP-induced sensitization of baroreceptors. The possibility that AVP also causes forearm vasodilation directly has not been examined.
Introduction
Arginine vasopressin (AVP)' is a neurohormone with potent vasopressor and antidiuretic properties (1) . AVP is an arterial vasoconstrictor when studied in vitro or in animal preparations (2, 3) . This vasoconstriction is mediated by a specific AVP receptor subtype, the VI receptor, which increases intracellular calcium levels. The renal hydroosmotic effects of AVP are mediated by a second receptor subtype, the V2 receptor, that increases intracellular cAMP. Vasopressin may also have vasorelaxant properties that belie its name. Several studies have suggested the existance of extrarenal V2 receptors that may mediate a vasodilatory effect of AVP (4) (5) (6) (7) . In addition, AVP may have variable effects on the sympathetic nervous system. AVP directly augments nerve terminal release of norepinephrine (8) , but also causes withdrawal of sympathetic tone via sensitization of baroreflexes (9) (10) (11) (12) (13) (14) . Other evidence suggests additional mechanisms that might contribute to an AVP-mediated vasodilator effect; AVP increases release of vasodilator prostaglandins in vitro and in animals (15) (16) (17) , causes release of endothelium-dependent relaxant factor(s) (18) , and decreases renin secretion (19) (20) (21) (22) .
The role of vasopressin in supporting the blood pressure of humans remains unclear. Plasma AVP levels increase in response to orthostasis, hypotension, dehydration, exercise, nausea, and are elevated in some patients with congestive heart failure (23) (24) (25) (26) (27) (28) (29) (30) . AVP is a potent splanchnic vasoconstrictor (31), but when infused intravenously into normal subjects at high physiologic doses (achieving plasma levels of 200-300 pg/ml), the expected rise in blood pressure is either absent or quite modest (32, 33) . Aylward and co-workers recently demonstrated that forearm blood flow (FBF) increased in normal subjects in response to intravenous AVP administration but interpreted this response to be due to systemic baroreceptor sensitization and withdrawal of sympathetic activity (32) . This was supported by additional studies in humans that demonstrated, by direct nerve recording, that sympathetic activity decreased during intravenous infusion of vasopressin (11, 12) . These authors did not test the possibility that the vasodilation also may have resulted from a direct vasorelaxant effect of AVP.
Accordingly, the objectives of the present investigation were: (a) to determine the direct vascular effect of AVP in the human forearm independent of reflex effects by measuring the FBF response to local IA AVP infusion compared with that in the noninfused arm; (b) to clarify the role of specific AVP receptors in mediating these vascular effects via either coadministration of a specific V1 vasopressin receptor antagonist or by infusing dDAVP, a vasopressin V2 receptor agonist; (c) to relate local changes in vasodilator prostaglandin levels to changes in FBF during AVP infusion; and (d) to determine whether AVP's vascular effects were regionally selective by measuring blood flow to the finger as well as to the forearm.
Methods
Subjects. 22 normal volunteers, 13 males and 9 females, were studied in three protocols. The age of the subjects was 26±5 yr (mean±SD), ranging from 19 to 34 yr. All subjects underwent a screening medical history, physical examination, and laboratory testing, which included complete blood count, serum electrolytes, blood glucose, serum trans-aminases, blood urea nitrogen, and serum creatinine, to exclude cardiac, renal, or hepatic disease. The protocol was approved by the Committee for the Protection of Human Subjects of the Brigham and Women's Hospital, and each volunteer gave written informed consent.
Experimental protocols. Each subject was studied in the morning after an overnight fast. Alcohol, caffeine, and cigarettes were all prohibited within 12 h of the study. Under local anesthesia and sterile conditions, a polyethylene catheter was inserted into a brachial artery of each subject. Additional catheters were inserted into an antecubital vein in each arm. The vascular research laboratory was noise free and lights were dimmed. Room temperature was controlled at 22°C. All subjects rested for at least 30 min after catheter placement to establish a stable baseline before data collection.
Three experimental protocols were performed. In the first protocol, the dose-response relationship of IA AVP and forearm blood flow was determined in seven normal subjects. To examine direct vascular AVP effects, the hormone was infused intraarterially. FBF responses were measured in the experimental arm and compared with those obtained in the contralateral, control arm. Heparinized normal saline (1.0 U/ml) was infused during all baseline periods. After establishment of a stable hemodynamic baseline, AVP was infused at 0.01, 0.1, 1.0, and 10 ng/kg per min dosages in sequential 20-min study periods. The infusion rate was constant (0.3 ml/min) during all study periods in all protocols (Harvard Apparatus, S. Natick, MA). Blood for determination of plasma AVP and vasodilator prostaglandin concentrations was collected after 15 min of AVP infusion at each dose. The systemic hemodynamic and FBF response to AVP was determined 20 min after initiation of each infusion dose. Two additional subjects served as time and vehicle controls by undergoing an identical protocol with intra-arterial infusion of vehicle (chlorobutanol) alone.
In the second protocol, 10 additional normal subjects were studied in order to examine the systemic hemodynamic, forearm, and digital blood flow responses to IA AVP infusion alone and after pretreatment with a vasopressin V 
This study used methodology identical to that used in the first protocol. Blood pressure, heart rate, and forearm and digital blood flow responses were determined during five sequential 20-min study periods: (i) baseline, (ii) IA infusion of AVP at 1.0 ng/kg per min, (iii) a second baseline, (iv) intravenous administration of 0.5 mg of the VI AVP antagonist alone, and (v) rechallenge with AVP at 1.0 ng/kg per min during VI AVP receptor blockade.
In the third protocol, the systemic hemodynamic, forearm, and digital blood flow dose-response relationship to IA administration of the V2 agonist I-desamino [8-i- Brachial artery blood pressure and a lead II electrocardiographic trace were recorded on a strip chart recorder (Model 4600; Gould, Inc.). The heart rate (HR, beats/minute) was calculated from the mean R-R interval of ten cardiac cycles.
Forearm and digital bloodflow measurements. FBF (in milliliters/ 100 milliliters per minute) and digital blood flow (DBF; milliliters/ 100 milliliters/minute) were measured by venous occlusion strain gauge plethysmography, using calibrated mercury-in-silastic strain gauges (D. E. Hokanson, Inc., Issaquah, WA). Bilateral forearm strain gauges were placed 5 cm distal to the antecubital creases of each arm, with each arm supported above right heart level. The finger strain gauge and venous occlusion cuff were placed immediately distal and proximal, respectively, to the proximal interphalangeal joint on the second digit of the experimental arm. Forearm and digital venous occlusion pressures were both 40 mmHg. When both DBF and FBF were measured, DBF was determined first. Circulation to the hand was then arrested by inflating a wrist cuff to suprasystolic pressures for 1 min before each FBF determination. Each forearm and digital blood flow determination comprised at least five separate measurements performed at 10-1 5-intervals.
Hormonal measurements. Antecubital venous blood was collected into heparinized tubes, immediately placed on ice, and centrifuged at 2°C. The plasma was separated and stored at -70°C before assay. Plasma AVP was measured in plasma extracts in triplicate using a commercial polyclonal antibody (Arnel Pharmaceuticals. New York, NY) at a final dilution of 1:75,000 AVP standard (Bachem, Torrence, CA) and ['25I]arginine vasopressin (New England Nuclear, Boston, MA) as previously described (33) . The assay has a sensitivity of 0.2 pg/tube, < 0.005% cross-reactivity with oxytocin, 100% cross-reactivity with the V1 receptor antagonist, and an intraassay coefficient of variation of 9%.
The vasodilator prostaglandin PGE2 and the PGI2 metabolite, 6- keto-PGF,a, were determined in unextracted plasma extracts from forearm venous effluent by RIA as described (34) . In this radioimmunoassay, PGE2, 6-keto-PGF2a, thromboxane B2, and PGE2-, and PGF2 a-M cross-react < 1%. These prostaglandin assays have a sensitivity of 10 pg/ml and intraassay coefficient of variation of < 10%.
Statistical analysis. Forearm and digital blood flow, blood pressure, heart rate, and hormonal data are presented as mean±SE. Data from each study period were compared by analysis of variance for repeated measures for parametric data, followed by Neuman-Keuls posthoc testing for statistical significance. Friedman's analysis of variance for repeated measures was used for nonparametric data. Statistical significance was accepted at the 95% confidence level (P < 0.05).
Results
Protocol 1: IA A VP dose-response relationship. was also unchanged at all but the highest dose, when a small rise was observed (P < 0.05 compared with baseline).
The FBF response to AVP is displayed in Fig. 1 . Baseline FBF was the same in both arms (3.5±0.4 and 3.4±0.4 ml/100 ml per min, experimental and control arms, respectively). FBF tended to increase in the experimental arm at the 0.1 ng/kg per min dose (to 4.5±1.0 ml/100 ml per min) and increased significantly at the 1.0 ng/kg per min infusion rate (to 5.4±0.9 ml/100 ml per min, P < 0.05 compared with baseline). FBF in the experimental arm reached a plateau at the 10 ng/kg per min infusion rate (5.5±1.3 ml/100 ml per min). FBF in the control arm was unchanged at all but the highest infusion rate; at this dose, FBF increased to 6.1±1.5 ml/100 ml per min (P < 0.05 compared with baseline). In contrast, during vehicle infusion, no change in SBP or bilateral FBF occurred (Table II). Table III displays the plasma AVP levels achieved in the venous blood from the experimental and control arms. Venous AVP levels were comparable in both arms at baseline. Plasma AVP increased significantly in the experimental arm at the 0. l-ng/kg per min dose (P < 0.01 compared with baseline), and continued to increase significantly with higher AVP infusion doses (1.0-and 10-ng/kg per min doses compared to baseline, P < 0.01). These levels were unchanged in the control arm at the lower infusion doses, but increased significantly at the 1.0-ng/kg per min dose and the 10-ng/kg per min dose (P < 0.01). The AVP level was 261 pg/ml in the experimental arm at the 1.0-ng/kg per min dose that was associated with significant forearm vasodilation. In the control arm, vasodila- tion occurred only at the highest infusion dose and was associated with a comparable AVP level, 228 pg/ml. Thus, intraarterial AVP administration elicited a dose-dependent increase in FBF in the experimental arm. This dose-dependent relationship was shifted to the right in the control arm.
Protocol 2: Effect ofIA A VP after vasopressin VI receptor blockade. This protocol was designed to determine whether forearm vasodilation could be blocked by the vasopressin VI receptor antagonist. After initial baseline values were recorded, AVP was infused intraarterially at the dose previously determined to cause maximal forearm vasodilation (1.0 ng/kg per min). Baseline conditions were reestablished, and the effects of intravenous administration of the V1 receptor antagonist alone were determined. Previous investigation has demonstrated that this V1 receptor antagonist has a duration of action of > 2 h (35). Thus, VI receptor blockade should have persisted during subsequent rechallenge with AVP. Table IV displays the systemic hemodynamic response observed in this protocol. Systolic blood pressure was unchanged during all study periods. Diastolic blood pressure decreased by 6 mmHg (P < 0.01) and heart rate rose by 15 beats/minute (P < 0.01) when AVP was infused during simultaneous V1 receptor blockade.
The forearm blood flow response in this protocol is depicted in Figs. 2 and 3. FBF was 2.3±0.2 and 2.4±0.3 ml/100 ml per min in the experimental and control arms, respectively, during the baseline period. FBF rose significantly to 4.5±1.1 ml/100 ml per min (P < 0.05) in the experimental arm during the initial IA AVP infusion. This vasodilator response was Table I. * P < 0.01 compared with baseline.
Serial vehicle doses were administered as per protocol 1. Abbreviations: FBF(E/C), forearm blood flow (ml/100 ml per min) in experimental and control arms, respectively. (Figs. 3 and 4) . DBF decreased significantly during AVP infusion (from 7.7+±1.8 to 3.6±0.9 ml/100 ml per min, P < 0.05). Basal DBF values were reestablished after cessation of the AVP infusion. Administration of the AVP antagonist alone did not change digital blood flow (5.9±2.0 ml/100 ml per min, NS). After administration of the AVP antagonist, the vasoconstrictor response to the second AVP challenge was abolished (6.4±2.7 ml/100 ml per min, NS).
Bilateral forearm venous plasma vasopressin levels were determined in seven subjects during this protocol (Table V) . Plasma AVP levels were determined at baseline, during AVP challenge, and during the second baseline before administration of the VI antagonist. AVP determinations after administration of the VI antagonist were not performed due to the 100% cross-reactivity of AVP and its methyl-tyrosine substituted analogue in this assay. Baseline plasma AVP concentrations were equal in both arms. In the control arm, AVP infusion at 1.0 ng/kg per min increased the venous AVP concentration to a comparable level (P < 0.01 compared with baseline) as that measured in protocol 1. Plasma AVP concentration returned to control values during the second baseline period (P = NS). In the experimental arm, venous AVP concentration rose to only 45% of that achieved during the serial AVP infusions of protocol 1, but elicited a comparable increase in FBF. Additionally, despite the return of FBF to control values during the second baseline period, venous AVP levels remained slightly elevated (P < 0.05). Protocol 3: dDA VP-FBF dose-response relationship. Table  VI displays the systemic hemodynamic response to incremental doses of IA dDAVP. There were no significant changes in systolic blood pressure in response to the lower two dDAVP doses, but SBP decreased significantly at the highest dose (P < 0.05). Diastolic blood pressure and heart rate were unchanged at all doses.
The FBF response to intraarterial dDAVP is displayed in Fig. 5 . FBF was equal in both arms at baseline (2.1±0.1 and 2.3±0.3 ml/100 ml per min, experimental and control arms, respectively). FBF increased significantly in the experimental arm at the 0.l-ng/kg per min dose (to 4.5±0.6 ml/100 ml per min, P < 0.05) and increased further at the 1.0-ng/kg per min infusion rate (to 8.8±2.4 ml/100 ml per min, P < 0.01 compared with baseline). FBF in the control arm was unchanged at all infusion rates.
DBF was little changed during dDAVP infusion. Baseline DBF in the experimental arm was 5.8±1.9 ml/ 100 ml per min, and 7.0±2.9. 7.4±2.6, and 5.4±1.6 ml/ 100 ml per min, respectively during the 0.01-, 0.1-, and 1.0-ng/kg per min dDAVP infusion dosages. The changes in DBF during dDAVP infusion are illustrated in Fig. 6 . Whereas FBF increased in a dosedependent manner, DBF was unchanged at all infusion doses. Vasodilator prostaglandin levels. Venous blood obtained from the experimental and control arms of seven subjects in protocols 1 and 2 was assayed for PGE2 and 6-keto-PGF,a levels to determine the relationship of the vasodilator effect to changes in local prostaglandin concentrations (Table VII) . At baseline, there was no significant difference in the PGE2 or 6-keto-PGF,a levels in the control and experimental arms.
Vasodilator prostaglandin levels in the experimental and control arms did not change significantly from baseline whether assessed at the 1.0-ng/kg per min infusion dose or at the dose associated with peak forearm vasodilation.
Discussion
The potent vasoconstrictor effect of arginine vasopressin has been demonstrated in vitro (2) and during high dose infusion in animals (21, (36) (37) (38) . In humans, however, only modest increases in blood pressure or systemic vascular resistance occur during AVP infusion (22, 31, 32) . Intravenous administration of AVP increases FBF (32) . These discrepant physiologic effects have heretofore been attributed to species differences or to the withdrawal of sympathetic efferent activity by sensitization ofbaroreflexes. The present investigation demonstrates (a) that AVP elicits dose-dependent vasodilation in the human forearm, (b) that AVP-induced forearm vasodilation is a direct vascular effect, independent of systemic baroreflex responses, (c) that the vasopressinergic V2 receptor may be responsible for the vasodilatory response, (d) that AVP fore- arm vasodilation is not a homogeneous effect, inducing regionally selective forearm vasodilation and digital vasoconstriction, and (e) that infusion of AVP in a wide range ofdoses causes only minor net effects on blood pressure.
Vasopressin-induced forearm vasodilation in humans. Though two prior human studies have demonstrated that systemic AVP infusion increases limb blood flow, the direct vascular effect of AVP has not previously been demonstrated (32, 39) . Kitchin et al. in 1957 (39) , observed an increase in FBF during intravenous AVP infusion (at 6 ng/kg per min).
These authors investigated this phenomenon further by intrabrachial artery AVP infusion, but failed to observe an increase in FBF; however, the IA infusion rate was low (-0.06 ng/kg per min). Similar infusion rates in our study also failed to change FBF. Aylward et al. recently assessed the forearm blood flow response to intravenous AVP infusion and lower body negative pressure in normal subjects. No change in FBF occurred when plasma AVP levels were raised to 24±4 pg/ml by a 0.4-ng/kg per min intravenous infusion, but FBF increased when plasma AVP rose to 290±41 pg/ml during a 4-ng/kg per min infusion (32) . The reflex vasodilator response to withdrawal of lower body negative pressure was interpreted as documenting AVP-induced baroreceptor sensitization and withdrawal of sympathetic tone. This was based on direct measurements of nerve activity in humans showing a decline in 6-keto-PGF,a (pg/ml)
No interarm or intertreatment effects were statistically significant. For abbreviations, see Table III . (1 1, 12 ) and experiments in animals showing sensitization of baroreceptors (13, 14) . Thus, sympathetic withdrawal was presumed by the authors to be the cause of the forearm vasodilation observed during AVP infusion.
In this study, we elucidated an additional mechanism whereby AVP affects forearm vascular resistance. Forearm vasodilation occurred in the experimental arm in the absence of FBF changes in the noninfused arm, suggesting that the effect is a direct, not a reflex phenomenon. Furthermore, our results demonstrate that AVP-induced vasodilation is a dose-dependent phenomenon. Comparable forearm vasodilation was observed in each arm as plasma AVP levels increased; however, the dose-response curve of the control arm was shifted rightward compared with the experimental arm.
Evidence for a vascular vasopressin V2 receptor. The synthesis of AVP antagonists by Manning et al. has been rapidly followed by their application as physiologic probes, yielding significant insights into the role of specific AVP receptors (40, 41) . The VI receptor is present on rat and human vascular smooth muscle (1) and mediates AVP-induced vasoconstriction. The VI receptor antagonist used in this study has a V2/V1 receptor specificity of 1:30 compared with AVP. It has antivasopressor (pA2 = 8.62), in vivo antioxytocic (pA2 = 6.62), and weak V2 receptor agonist (0.31 U/mg) properties (42), and a markedly increased half-life compared with AVP (35, 42, 43) .
The V2 receptor has heretofore been localized in renal collecting ducts and mediates AVP antidiuretic affects via activation of the adenylate cyclase system. It has also been localized in brain, where its significance is unknown. Despite synthesis of vasopressin antagonists with high V2 receptor specificity in other mammalian species, no antagonist retains V2 specificity in humans. Thus, investigation of V2 receptor-specific physiologic effects in man is presently limited to use ofV2 agonist peptides. 1-desamino[8-D-arginine] vasopressin, or dDAVP, is such an analogue characterized by slightly increased V2 receptor affinity (antidiuretic activity = 1,200 U/mg, 1.7 times that of AVP) and greatly diminished VI receptor affinity, (activity = 0.39 U/mg, 1/3,000th that of its parent peptide); overall, the V2/VI affinity ratio is -2,054:1 (42, 44). dDAVP also demonstrates a prolonged plasma halflife compared with AVP (t1/2 of -55 min) (45) .
Despite advances in understanding receptor-mediated interactions of AVP with vascular smooth muscle, the physiologic effects of AVP in normal and pathologic states remains controversial. Systemic AVP infusion in conscious dogs increases mean arterial pressure and peripheral resistance, decreases cardiac output, and decreases skeletal muscle, pancreatic, mesenteric, myocardial, and cutaneous blood flow as determined by injection of radioactive microspheres (46, 47) . Further study of the hemodynamic effects of infusion of AVP or its analogues, however, in animals has implicated a possible role of V2 receptors in causing regional or systemic vasodilation. Liard and co-workers recently demonstrated that intraaxillary arterial infusion of AVP in conscious dogs decreased skin and compact skeletal bone blood flow, but skeletal muscle blood flow was preserved (48) . Administration of either 4-valine-8-D-AVP (VDAVP, a selective V2 agonist) or AVP during VI receptor blockade decreases systemic vascular resistance and increases cardiac output (4, 6, 38) .
The physiologic significance of these findings has also been investigated. Dogs subjected to dehydration demonstrate increased plasma AVP levels (-10 pg/ml); in response to administration of a VI antagonist, cardiac output and skeletal muscle blood flow increase (5) . Plasma AVP also increases during hypovolemic hypotension in animals; administration ofV 1 receptor antagonist potentiates the hypotensive response to hemorrhage. These responses have been interpreted to suggest that Vl receptors mediate a significant pressor effect in these conditions (49-5 1) . However, Vl blockade in these studies may have unmasked a significant V2 vasodilation effect.
As in previous studies, administration of a VI receptor antagonist alone to normal subjects in this study was without significant effects on blood pressure or heart rate (35 (18) . In any circulation, the net effect of AVP on blood flow may be the result of the balance of direct AVP VI and V2 receptor effects, and the effect of AVP on sympathetic activity in that circulation.
Effect ofA VP infusion on systemic hemodynamics. In this study, IA AVP administration elicited no pressor effect, and at 10 ng/kg per min alone and at 1.0 ng/kg per min during VI antagonism was associated with a decline in diastolic blood pressure and rise in heart rate ( Tables I, II, and IV) . This may be due to the summation of AVP's vasoconstrictor and vasodilator actions on regional circulations. Schwartz et al. reported that systemic AVP administration during VI antagonism caused no change in blood pressure, but increased heart rate (55) . The administration to humans of the more selective V2 agonist dDAVP, however, lowers blood pressure and increases heart rate (7, 56) . Thus, the modest changes that AVP causes in blood pressure may be due to a balance of VI -and V2-mediated effects on regional vascular resistance.
Physiologic significance. Significant forearm vasodilation was observed in this study at plasma concentrations that may have physiologic relevance. In the small population examined in this study, forearm vasodilation was noted at local plasma AVP concentrations of 100-200 pg/ml. AVP may also cause significant forearm vasodilation at substantially lower plasma levels. It is notable that forearm blood flow tended to increase in our dose-response protocol at the 0. l-ng/kg per min infusion, when plasma levels were 70 pg/ml. In a larger study population, this might well have reached statistical significance.
During nonstress states, when AVP levels are from 1.0 to 5.0 pg/ml, AVP may exert its primary effects as an antidiuretic hormone. Moderate stress (e.g. exercise, nausea) may increase plasma AVP levels to the 20-50 pg/ml range (25, 26) ; at these levels, the V2 vasodilator effect may cause skeletal muscle vasodilation and, in concert with other endothelial, myogenic, and metabolic vasodilator stimuli may act to counterbalance sympathetic vasoconstriction. More profound stress (e.g., hypovolemic hypotension, surgical trauma, congestive heart failure) may increase AVP levels to the 50-500 pg/ml range, and the VI vasoconstrictor effect on skin, splanchnic, and skeletal muscle may predominate (23, 24, (27) (28) (29) (30) .
The topographical distribution of vasopressin VI and V2 receptors in regional vascular beds is not known, nor is the regulation of these receptors in pathophysiologic states. AVP has approximately equal affinity for VI and V2 receptors. Thus, in addition to renal hydroosmotic effects, vasopressin might serve as an important hormonal modulator of regional blood flow.
